Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
The current 0JDK market cap is 4.95B. The company's latest EPS is USD -1.2211 and P/E is -2.95.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 1.19M | 164.07M |
| Operating Income | -261.94M | -342.7M | -398.88M | -460.56M | -395.28M |
| Net Income | -259.58M | -342.25M | -395.89M | -444.04M | -372.18M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 768.46M | 777.33M | 663.98M | 780.35M | 910.43M |
| Total Liabilities | 111.96M | 155.67M | 164.34M | 195.74M | 200.02M |
| Total Equity | 656.5M | 621.66M | 499.64M | 584.61M | 710.41M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -205.13M | -227.94M | -292.76M | -361.82M | -352.98M |
| Investing | -317.85M | 132k | 256.46M | -155.24M | -96.41M |
| Financing | 576.42M | 239.27M | 190.15M | 462.96M | 390.66M |
| Market Cap | 4.95B |
| Price to Earnings Ratio | -2.95 |
| Price to Sales Ratio | 6.69 |
| Price to Cash Ratio | 9.48 |
| Price to Book Ratio | 1.54 |
| Dividend Yield | - |
| Shares Outstanding | 304.78M |
| Average Volume (1 week) | 52.29k |
| Average Volume (1 Month) | 48.4k |
| 52 Week Change | 0.00% |
| 52 Week High | 16.25 |
| 52 Week Low | 16.25 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Iovance Biotherapeutics Inc |
| Address |
2140 s dupont hwy camden, delaware 19934 |
| Website | https://www.iovance.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
